{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Asciminib+%28ABL001%29", "query": { "intervention": "Asciminib (ABL001)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 29, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Asciminib+%28ABL001%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T17:36:16.068Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07250087", "title": "Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Asciminib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2026-01-21", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-25T17:36:16.068Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07250087" }, { "nct_id": "NCT05143840", "title": "Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloid Leukemia, Chronic Phase", "Adult CML", "Leukemia, Myeloid", "Leukemia,Myeloid, Chronic" ], "interventions": [ { "name": "Single Agent Asciminib", "type": "DRUG" }, { "name": "Low TKI", "type": "COMBINATION_PRODUCT" }, { "name": "Elective Free Treatment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2022-04-22", "completion_date": "2032-02", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-25T17:36:16.068Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Augusta, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05143840" }, { "nct_id": "NCT04666259", "title": "Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Myelogenous Leukemia - Chronic Phase" ], "interventions": [ { "name": "ABL001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 56, "start_date": "2021-05-25", "completion_date": "2024-06-26", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-09-25T17:36:16.068Z", "location_count": 26, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Long Beach, California + 21 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04666259" }, { "nct_id": "NCT03595917", "title": "ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia", "Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis", "Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL" ], "interventions": [ { "name": "ABL001", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marlise Luskin, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-07-24", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-09-25T17:36:16.068Z", "location_count": 4, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Buffalo, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03595917" }, { "nct_id": "NCT04925479", "title": "Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myeloid Leukemia, Philadelphia Positive" ], "interventions": [ { "name": "Asciminib Pediatric formulation group", "type": "DRUG" }, { "name": "Asciminib Adult formulation group", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 34, "start_date": "2021-12-27", "completion_date": "2031-10-01", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-09-25T17:36:16.068Z", "location_count": 8, "location_summary": "Indianapolis, Indiana • Boston, Massachusetts • Jackson, Mississippi + 5 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04925479" }, { "nct_id": "NCT06308588", "title": "Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Philadelphia Chromosome-Positive", "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Asciminib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2024-08-05", "completion_date": "2029-05-01", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-09-25T17:36:16.068Z", "location_count": 2, "location_summary": "The Bronx, New York • Houston, Texas", "locations": [ { "city": "The Bronx", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06308588" }, { "nct_id": "NCT07644351", "title": "A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2024-12-16", "completion_date": "2025-09-17", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-09-25T17:36:16.068Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07644351" }, { "nct_id": "NCT07604233", "title": "Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myeloid Leukemia" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Asciminib", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2026-11-30", "completion_date": "2033-06-03", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-25T17:36:16.068Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07604233" }, { "nct_id": "NCT05384587", "title": "Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myelogenous Leukemia - Chronic Phase" ], "interventions": [ { "name": "asciminib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 34, "start_date": "2022-11-11", "completion_date": "2027-10-17", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-09-25T17:36:16.068Z", "location_count": 80, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 71 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Cerritos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05384587" }, { "nct_id": "NCT06773936", "title": "Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia", "CD19+ Acute Leukemia" ], "interventions": [ { "name": "Induction Phase", "type": "DRUG" }, { "name": "Re-Induction Phase", "type": "DRUG" }, { "name": "Post-Remission", "type": "DRUG" }, { "name": "Maintenance", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 55, "start_date": "2026-04-13", "completion_date": "2033-07", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-25T17:36:16.068Z", "location_count": 11, "location_summary": "Orange, California • Detroit, Michigan • Albuquerque, New Mexico + 8 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Lake Success", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06773936" } ] }